摘要人凝血因子Ⅶ(human coagulation factorⅦ,hFⅦ)是参与血液凝血级联反应的蛋白之一,在凝血过程中发挥极其重要的作用.hFⅦ主要用于治疗和预防先天性或获得性血友病患者的出血,还可用于非血友病患者的创伤性大出血.通过基因工程技术制备hFⅦ不仅安全,而且还易于大规模生产.已有文献报道在利什曼原虫、昆虫细胞、多种哺乳动物细胞以及转基因兔乳腺中成功表达重组hFⅦ.因此,开发能高效表达重组hFⅦ的表达系统,将使大规模生产hFⅦ成为可能.

abstractsHuman coagulation factor Ⅶ (hFⅦ) is one of the proteins involved in blood coagulation cascade,and plays an important role in the coagulation process.hFⅦ is indicated for the prevention and treatment of bleeding episodes in congenital or acquired hemophilia patients.In addition,hFⅦ can also be used for treatment of bleeding in trauma patients.Recombinant hFⅦ (rhFⅦ) produced by genetic engineering techniques is not only safe,but also easy for mass production.It is reported that rhFⅦ has been successfully expressed in Leishmania,insect cells,a variety of mammalian cells and mammary gland of transgenic rabbits.Therefore,developing a expression system,which can express high-level hFⅦ,makes mass production of rhFⅦ possible.